| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/02/2004 | EP1424067A1 Injectable foam and novel pharmaceutical applications thereof |
| 06/02/2004 | EP1424062A1 Screening composition containing at least one dibenzoylmethane derivative and at least one 3-(2-azacycloalkylidene)-1,3-dihydro-indol-2-one; photostabilisation process |
| 06/02/2004 | EP1423739A1 Source wavelength shifting apparatus and method for delivery of one or more selected emission wavelengths |
| 06/02/2004 | EP1423707A1 Methods of screening molecules that are used to prevent cardiovascular diseases |
| 06/02/2004 | EP1423704A1 Diagnostic and therapeutic use of f-box proteins for alzheimer's disease and related neurodegenerative disorders |
| 06/02/2004 | EP1423697A2 Secreted proteins |
| 06/02/2004 | EP1423693A1 Erythropoietin and anti-tumor necrosis factor alpha combination therapy |
| 06/02/2004 | EP1423511A2 Nucleic-acid associated proteins |
| 06/02/2004 | EP1423503A2 Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd |
| 06/02/2004 | EP1423425A2 Receptor, the use thereof, and mouse antibodies |
| 06/02/2004 | EP1423424A2 Mouse farnesoid x receptor sequences for use in comparative pharmacology |
| 06/02/2004 | EP1423422A2 A caspase- 8 binding protein, its preparation and use |
| 06/02/2004 | EP1423415A2 Intracellular signaling molecules |
| 06/02/2004 | EP1423390A2 Purine inhibitors of phosphodiesterase (pde) 7 |
| 06/02/2004 | EP1423382A2 Pyrazole-derived kinase inhibitors and uses thereof |
| 06/02/2004 | EP1423380A1 Pyrazole-derived kinase inhibitors and uses thereof |
| 06/02/2004 | EP1423376A1 Bicyclic compound, production and use thereof |
| 06/02/2004 | EP1423359A1 C2-disubstituted indane-1-ones and their derivatives, method for their production and their use as medicaments |
| 06/02/2004 | EP1423169A2 Potentiator composition comprising a terpene for enhancing the therapeutical effect of antitumoral agents in the treatment of cancer |
| 06/02/2004 | EP1423167A1 Method for treating alzheimer's disease using quinaldoyl-amine derivatives of oxo- and hydroxy-substituted hydrocarbons |
| 06/02/2004 | EP1423166A2 Non-peptide ccr1 receptor antagonists for the treatment of progressive renal fibrosis |
| 06/02/2004 | EP1423165A2 Intravaginal administration of an aromatase inhibitor for the treatment of oestrogen-dependent proliferative disorders |
| 06/02/2004 | EP1423147A1 Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| 06/02/2004 | EP1423146A1 Composition for treating parkinson's disease containing a cb1 receptor antagonist and a product activating dopaminergic neurotransmission in the brain |
| 06/02/2004 | EP1423145A1 Compositions for the treatment of parkinson's disease containing a cb1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain |
| 06/02/2004 | EP1423144A2 Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease |
| 06/02/2004 | EP1423142A1 Helicobacter pylori vaccination with a combination of caga, vaca and nap proteins |
| 06/02/2004 | EP1423139A2 New use of artemin, a member of the gdnf ligand family |
| 06/02/2004 | EP1423132A2 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 06/02/2004 | EP1423128A2 Methods for the treatment of chronic pain anc compositions therefor |
| 06/02/2004 | EP1423127A1 Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors |
| 06/02/2004 | EP1423122A2 Compositions and methods relating to novel benzodiazepine compounds and targets thereof |
| 06/02/2004 | EP1423116A1 Method of treating alcoholism or alcohol abuse |
| 06/02/2004 | EP1423114A2 Method and compositions for treating migraines |
| 06/02/2004 | EP1423105A2 Combinations of dmxaa and other anti-cancer agents |
| 06/02/2004 | EP1423104A1 Combination therapy for the treatment of neurological disorders |
| 06/02/2004 | EP1423103A2 Compositions and methods for modulation of darpp-32 phosphorylation |
| 06/02/2004 | EP1423102A1 Plaster for the treatment of dysfunctions and disorders of nail growth |
| 06/02/2004 | EP1423100A1 Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole |
| 06/02/2004 | EP1423099A1 A new extended release oral dosage form |
| 06/02/2004 | EP1423095A1 Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
| 06/02/2004 | EP1423081A2 Composition comprising glycosaminogycans and hyaluronidase inhibitors for the treatment of arthritic joints |
| 06/02/2004 | EP1423012A2 Isolation and mobilization of stem cells expressing vegfr-1 |
| 06/02/2004 | EP1274405B1 Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication |
| 06/02/2004 | EP1267832B1 SELF EMULSIFYING DRUG DELIVERY SYSTEM, wherein the fatty agent is optional |
| 06/02/2004 | EP1123097B1 Pharmaceutical composition containing decursin |
| 06/02/2004 | EP1114032B1 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors |
| 06/02/2004 | EP1063978B1 Method of treating neuroma pain |
| 06/02/2004 | CN1501942A Diaryl peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 06/02/2004 | CN1501940A Composition and method for inhibiting platelet aggregation |
| 06/02/2004 | CN1501928A Small molecule compositions for binding to hsp90 |
| 06/02/2004 | CN1501911A Phenethanolamine derivatives for treatment of respiratory diseases |
| 06/02/2004 | CN1501828A Dapd combination therapy with inosine monophosphate dehydrogenase inhibitor |
| 06/02/2004 | CN1501826A Device for percutaneous transdermal delivery having coated micro-protrusions |
| 06/02/2004 | CN1501810A Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis |
| 06/02/2004 | CN1501804A Acrochordon alleviation |
| 06/02/2004 | CN1501798A Medicinal compositions comprising diclofenac and ornoprostil |
| 06/02/2004 | CN1501797A Anti-proliferative drugs |
| 06/02/2004 | CN1501796A Treatment of type 2 diabetes mellitus using inhibitors of dipeptidyl peptidase IV |
| 06/02/2004 | CN1500524A Vehicle for topical delivery of anti-inflammatory compounds |
| 06/02/2004 | CN1151797C Tumor-blood-vessel growth inhibitor and medicinal composition |
| 06/02/2004 | CN1151792C Use of anti-oestrogens in preparation of drugs of male contraceptives |
| 06/02/2004 | CN1151789C Use of aryl (or heteroaryl) pyrrolyl methanol derivatives |
| 06/02/2004 | CN1151784C Quick absorption liquid composition |
| 06/02/2004 | CN1151781C Use of nitric oxide donors or nitric oxide inhibitors for regulation of cervical dilatation and extensibility |
| 06/02/2004 | CN1151777C Preparation for transport of active substance across barriers |
| 06/02/2004 | CN1151775C Method of treating dry eye disease with purinergic receptor agonists |
| 06/01/2004 | USRE38524 Dipeptide derivatives as growth hormone secretagogues |
| 06/01/2004 | US6743939 Phenylheteroalkylamine derivatives |
| 06/01/2004 | US6743824 Administering selegiline to patient in an amount sufficient to prevent, reduce or eliminate one or more of the symptoms associated with peripheral neuropathy |
| 06/01/2004 | US6743802 Alkyne-aryl phosphodiesterase-4 inhibitors |
| 06/01/2004 | US6743801 1,2,3,6-tetrahydropyrimidine-2-one compositions and therapeutic methods therewith for pain and inflammation |
| 06/01/2004 | US6743798 Cardiovascular disorders; vasorelaxation, inhibition of platelet aggregation, decrease in blood pressure; stimulation of soluble guanylate cyclase and an intracellular cgmp increase |
| 06/01/2004 | US6743782 Acyl derivative of 2'-deoxyadenosine; treating or preventing radiation, mutagen and sunlight-induced cellular damage, improving wound healing and tissue repair, ameliorating the effects of aging; enhance bioavailability |
| 06/01/2004 | US6743771 For solubilizing a conformationally altered protein, comprising a carboxylic acid anion of picolinic acid, its analogs, or derivatives thereof and a cation; treating alzheimer's disease or creutzfelds-jakob disease for example |
| 06/01/2004 | US6743433 Treatment of acne using alkanolamine compositions |
| 06/01/2004 | US6743424 Method for treating hyperthyroidism |
| 06/01/2004 | US6743415 Delivery of anti-migraine compounds through an inhalation route |
| 06/01/2004 | CA2092505C Pharmaceutical compositions containing l-carnitine or an acyl l-carnitine in combination with an ace-inhibitor for the treatment of cardiovascular disorders and a method for treating cardiovascular disorders |
| 05/27/2004 | WO2004044068A1 Disinfecting dip compositions and related methods |
| 05/27/2004 | WO2004043495A1 Delivery agent, method of delivering a target substance to cells, method for producing delivery agent, composition for producing delivery agent, and kit for producing delivery agent |
| 05/27/2004 | WO2004043481A2 Compositions containing peptide copper complexes and metalloproteinase inhibitors, and methods related thereto |
| 05/27/2004 | WO2004043479A1 Irrigation solution and method for inhibition of tumor cell adhesion, pain and inflammation |
| 05/27/2004 | WO2004043473A1 Composition for restoring damaged skin |
| 05/27/2004 | WO2004043472A1 Combination product of inhibitor of the src family of non-receptor tyrosine kinases and gemcitabine |
| 05/27/2004 | WO2004043464A1 Methods of using and compositions comprising immunomudulatory compounds for the treatment and management of myeloproliferative diseases |
| 05/27/2004 | WO2004043461A1 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
| 05/27/2004 | WO2004043460A1 Synergistic combinations with analgesic properties comprising n-acylated 4-hydroxyphenylamine derivatives |
| 05/27/2004 | WO2004043457A1 Cholesterol absorptions inhibitors for the treatment of autoimmune disorders |
| 05/27/2004 | WO2004043456A1 Cholesterol absorption inhibitors for the treatment of demyelination |
| 05/27/2004 | WO2004043454A1 Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropathies induced by anticancer agents |
| 05/27/2004 | WO2004043429A1 Combination therapy for postmenopausal female sexual dysfunction comprising an androgen, and at least one agent selected from an estrogen and an anti-muscarinic |
| 05/27/2004 | WO2004043393A2 Compositions for diabetes treatment and prophylaxis |
| 05/27/2004 | WO2004043392A2 Mucin synthesis inhibitors |
| 05/27/2004 | WO2004043378A2 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| 05/27/2004 | WO2004043377A2 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |
| 05/27/2004 | WO2004043341A2 Treatment for hemorrhagic shock |
| 05/27/2004 | WO2004043340A2 Alpha 5 beta 1 and its ability to regulate the cell survival pathway |
| 05/27/2004 | WO2004043338A2 Flavin n-oxides: new anti-cancer agents and pathogen eradication agents |
| 05/27/2004 | WO2004043226A2 Methods for predicting whether subjects with mild cognitive impairment (mci) will develop alzheimer's disease |